Form 8-K
 
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
 
 
 
FORM 8-K
 
 
CURRENT REPORT
 
 
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
 
 
Date of Report: December 19, 2002
(Date of earliest event reported)
 
 
INCYTE GENOMICS, INC.
(Exact name of registrant as specified in its charter)
 
 
Delaware
   
0-27488
   
94-3136539
(State or other jurisdiction
of incorporation)
   
(Commission
File Number)
   
(IRS Employer
Identification No.)
 
 
3160 Porter Drive, Palo Alto, California 94304
(Address of principal executive offices) (Zip Code)
 
 
Registrant’s telephone number, including area code: (650) 855-0555
 

 
Item 5.    Other Events.
 
The 2003 Annual Meeting of Incyte Genomics, Inc. (the “Company”) will be held on June 23, 2003 at such place and time as will be set forth in the Company’s proxy statement relating to that meeting. A stockholder proposal not included in the proxy statement for the Company’s 2003 Annual Meeting will be ineligible for presentation at the meeting unless the stockholder gives timely notice of the proposal in writing to the Secretary of the Company at the principal executive offices of the Company and otherwise complies with the provisions of the Company’s Bylaws. To be timely, the Company’s Bylaws provide that the Company must have received the stockholder’s notice not less than 60 days nor more than 90 days prior to the scheduled date of such meeting. However, if notice or prior public disclosure of the date of the annual meeting is given or made to stockholders less than 70 days prior to the meeting date, the Company must receive the stockholder’s notice by the earlier of (i) the close of business on the 10th day after the earlier of the day the Company mailed notice of the annual meeting date or provided such public disclosure of the meeting date and (ii) two days prior to the scheduled date of the annual meeting. For the Company’s 2003 Annual Meeting of Stockholders, stockholders must submit written notice to the Secretary in accordance with the foregoing Bylaw provisions not later than April 24, 2003.

-2-

 
SIGNATURE
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
Dated:    December 19, 2002.
 
INCYTE GENOMICS, INC.
By:
  
/s/    LEE BENDEKGEY
   
Lee Bendekgey
Executive Vice President and
General Counsel

-3-